OncoMatch/Clinical Trials/NCT05080556
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
Is NCT05080556 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carboplatin for ovarian cancer.
Treatment: Carboplatin — ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (cisplatin, carboplatin) — most recent regimen
Most recent regimen must have included platinum (cisplatin or carboplatin); Must have responded to most recent platinum treatment by CT or MRI or by GCIG CA125 response criteria
Must have received: PARP inhibitor
Must have previously received a PARP inhibitor
Cannot have received: combination chemotherapy regimens
Patients requiring treatment with combination chemotherapy regimens
Cannot have received: investigational agent
Treatment with any other investigational agent, or participation in another interventional clinical trial within 28 days prior to randomisation.
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify